|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Termine JD, Kleinman HK, Whitson SW, Conn
KM, McGarvey ML and Martin GR: Osteonectin, a bone-specific protein
linking mineral to collagen. Cell. 26:99–105. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bornstein P and Sage EH: Matricellular
proteins: Extracellular modulators of cell function. Curr Opin Cell
Biol. 14:608–616. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang
KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different
histologic types and its role in the outcome of invasive ductal
carcinoma. Breast J. 16:305–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Botti G, Scognamiglio G, Marra L, Collina
F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R,
Fulciniti F, et al: SPARC/osteonectin is involved in metastatic
process to the lung during melanoma progression. Virchows Arch.
465:331–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seno T, Harada H, Kohno S, Teraoka M,
Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits
cell migration and invasion in malignant gliomas. Int J Oncol.
34:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng J and Tang L: SPARC in Tumor
Pathophysiology and as a Potential Therapeutic Target. Curr Pharm
Des. 20:6182–6190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang B, Chen K, Xu W, Chen D, Tang W and
Xia TS: Integrative genomic analyses of secreted protein acidic and
rich in cysteine and its role in cancer prediction. Mol Med Rep.
10:1461–1468. 2014.PubMed/NCBI
|
|
10
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steinestel K, Eder S, Schrader AJ and
Steinestel J: Clinical significance of epithelial-mesenchymal
transition. Clin Transl Med. 3:172014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiery JP, Chua K, Sim WJ and Huang R:
Epithelial mesenchymal transition during development in fibrosis
and in the progression of carcinoma. Bull Cancer. 97:1285–1295.
2010.(In French). PubMed/NCBI
|
|
13
|
Chen J, Shi D, Liu X, Fang S, Zhang J and
Zhao Y: Targeting SPARC by lentivirus-mediated RNA interference
inhibits cervical cancer cell growth and metastasis. BMC Cancer.
12:4642012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soumaoro LT, Uetake H, Higuchi T, Takagi
Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: A
significant prognostic indicator for patients with colorectal
cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmittgen TD, Zakrajsek BA, Mills AG,
Gorn V, Singer MJ and Reed MW: Quantitative reverse
transcription-polymerase chain reaction to study mRNA decay:
Comparison of endpoint and real-time methods. Anal Biochem.
285:194–204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sova P, Feng Q, Geiss G, Wood T, Strauss
R, Rudolf V, Lieber A and Kiviat N: Discovery of novel methylation
biomarkers in cervical carcinoma by global demethylation and
microarray analysis. Cancer Epidemiol Biomarkers Prev. 15:114–123.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arnold SA and Brekken RA: SPARC: A
matricellular regulator of tumorigenesis. J Cell Commun Signal.
3:255–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Girotti MR, Fernández M, López JA,
Camafeita E, Fernández EA, Albar JP, Benedetti LG, Valacco MP,
Brekken RA, Podhajcer OL and Llera AS: SPARC promotes cathepsin
B-mediated melanoma invasiveness through a collagen I/α2β1 integrin
axis. J Invest Dermatol. 131:2438–2447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fenouille N, Tichet M, Dufies M, Pottier
A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari
A, et al: The epithelial-mesenchymal transition (EMT) regulatory
factor SLUG (SNAI2) is a downstream target of SPARC and AKT in
promoting melanoma cell invasion. PLoS One. 7:e403782012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miao L, Wang Y, Xia H, Yao C, Cai H and
Song Y: SPOCK1 is a novel transforming growth factor-β target gene
that regulates lung cancer cell epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 440:792–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wendt MK, Balanis N, Carlin CR and
Schiemann WP: STAT3 and epithelial-mesenchymal transitions in
carcinomas. JAKSTAT. 3:e289752014.PubMed/NCBI
|
